Correction: Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis [0.03%]
订正：核糖体修饰蛋白rimK样家族成员A通过激活甜菜碱-同型半胱氨酸S-甲基转移酶1改善肝脂肪变性
Han Yan,Wenjun Liu,Rui Xiang et al.
Han Yan et al.
Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial [0.03%]
有关未经治疗的不可切除性转移性结直肠癌患者使用改良后的序贯CAPOX/CAPECLIPISA+贝伐单抗进行一线治疗的II期临床试验
Sheng Li,Xiaoyou Li,Hanfeng Xu et al.
Sheng Li et al.
Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer (mCRC). This phase 2 trial (NCT04324476) aimed to evaluate efficacy and safety of alternating modified CAPOX (capecitabine and oxali...
Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial [0.03%]
仑伐替尼耐药肝细胞癌患者中仑伐替尼联合吉非替尼的疗效和安全性：前瞻性单组探索性试验
Yaoping Shi,Dan Cui,Lei Xia et al.
Yaoping Shi et al.
Lenvatinib, a multi-kinase inhibitor, has been approved as first-line treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is limited. We have shown previously that lenvatinib and epidermal growth factor receptor tyrosine...
Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer [0.03%]
HER2低表达转移性乳腺癌的循环肿瘤DNA基因组谱景分析
Zongbi Yi,Kaixiang Feng,Dan Lv et al.
Zongbi Yi et al.
The large population of HER2-low breast cancer patients necessitates further research to provide enhanced clinical guidance. In this study, we retrospectively analyzed 1071 metastatic breast cancer (MBC) patients and the circulating tumor D...
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial [0.03%]
安罗替尼联合化疗作为不可切除的胃肠癌肝转移患者一线治疗的一项多队列、多中心探索性试验
Jun-Wei Wu,Chen-Fei Zhou,Zheng-Xiang Han et al.
Jun-Wei Wu et al.
This multicohort phase II trial (ALTER-G-001; NCT05262335) aimed to assess the efficacy of first-line anlotinib plus chemotherapy for gastrointestinal (GI) cancer patients with unresectable liver metastases. Eligible patients with colorecta...
Cellular pathophysiology of Duchenne muscular dystrophy: insights from a novel rhesus macaque model [0.03%]
杜氏肌营养不良的细胞病理生理学：来自新型猕猴模型的启示
Alessandra Moretti,Christian Kupatt,Eckhard Wolf
Alessandra Moretti
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer [0.03%]
带有EGFR突变的非小细胞肺癌中CXCR1+中性粒细胞浸润调控第三代EGFR-TKI应答反应
Haowei Wang,Anwen Xiong,Xiaoxia Chen et al.
Haowei Wang et al.
Although third-generation Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) is standard of care for patients with EGFR-mutant Non-small cell lung cancer (NSCLC), little is known about the predictors of response or resis...
Integration of novel biomarkers in prospective trials: biological insights from CHOICE-01 [0.03%]
CHOICE-01试验中新型生物标志物的应用带来的生物学启示
Edward Christopher Dee,Puneeth Iyengar
Edward Christopher Dee
New insights into protein-protein interaction modulators in drug discovery and therapeutic advance [0.03%]
药物发现和治疗中的蛋白质相互作用调节剂的最新见解
Hossam Nada,Yongseok Choi,Sungdo Kim et al.
Hossam Nada et al.
Protein-protein interactions (PPIs) are fundamental to cellular signaling and transduction which marks them as attractive therapeutic drug development targets. What were once considered to be undruggable targets have become increasingly fea...
Fengyuan Zhang,Yidan Xia,Jiayang Su et al.
Fengyuan Zhang et al.
Neutrophils, the most abundant type of granulocyte, are widely recognized as one of the pivotal contributors to the acute inflammatory response. Initially, neutrophils were considered the mobile infantry of the innate immune system, tasked ...